STOCKHOLM: Karolinska Development AB (Nasdaq Stockholm: KDEV) announces the divestment of all its shares in the portfolio company Henlez ApS.

Following the transaction, Karolinska Development’s investment portfolio consists of eleven holdings.

Karolinska Development invested in Henlez ApS in 2022, in syndication with the Nordic venture capital firm Eir Ventures. Henlez is a privately held Danish dermatology company focused on hidradenitis suppurativa.

Prior to the divestment, Karolinska Development’s ownership in Henlez amounted to 15%.

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams.

The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.